RxDoctor Payments Data

Roger Cappucci, MD

Cardiovascular Disease · Scarsdale, NYNPI 1649378225

Payments from drug & device makers

$304in general payments, 2019–2025

Across 6 payments — averaging $50.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$124
  • Medtronic$109
  • AbbVie$26
  • Biotronik Inc.$23
  • Merck$22

What the payments were for

  • Food & beverage$25985%
  • Education$4515%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific2$124
Medtronic1$109
AbbVie1$26
Biotronik Inc.1$23
Merck1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$304 in reported general payments places this provider in the 20th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$512,386
Medicare patients
1,375
Services billed
4,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban776$756,519
EntrestoSacubitril/Valsartan247$228,950
XareltoRivaroxaban167$193,828
Repatha SureclickEvolocumab178$163,447
JardianceEmpagliflozin47$45,087
FarxigaDapagliflozin Propanediol38$40,270
Praluent PenAlirocumab53$32,066
VascepaIcosapent Ethyl42$25,104
Ezetimibe547$18,403
BrilintaTicagrelor27$16,139
Atorvastatin Calcium1,147$14,679
Rosuvastatin Calcium903$14,470
Metoprolol Succinate789$11,834
NexletolBempedoic Acid20$10,082
Valsartan373$9,326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$26$3,34834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Scarsdale

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →